| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 03/07/2002 | DE10038722A1 Verfahren zur Reduzierung von spezifischen Immunreaktionen A process for the reduction of specific immune responses |
| 03/07/2002 | CA2424052A1 Packaging of positive-strand rna virus replicon particles |
| 03/07/2002 | CA2421893A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | CA2421055A1 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 03/07/2002 | CA2420869A1 Compounds having activity as inhibitors of cytochrome p450rai |
| 03/07/2002 | CA2420832A1 Methods and reagents for protease inhibition |
| 03/07/2002 | CA2420667A1 Quinoline-(c=o)-(di-,tri- and tetrapeptide) derivatives as caspase inhibitors |
| 03/07/2002 | CA2420659A1 Genes expressed in the cell cycle |
| 03/07/2002 | CA2420591A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/07/2002 | CA2420363A1 Pyrazole derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | CA2420122A1 7-oxo pyridopyrimidines |
| 03/07/2002 | CA2420105A1 Human kinases |
| 03/07/2002 | CA2420103A1 Modulation of fas and fasl expression |
| 03/07/2002 | CA2419841A1 Novel cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications |
| 03/07/2002 | CA2419472A1 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 03/07/2002 | CA2419399A1 Nucleoside derivatives for the treatment of hepatitis c |
| 03/07/2002 | CA2419342A1 G-protein coupled receptors |
| 03/07/2002 | CA2419251A1 Nucleic acid constructs including a novel t-cell active promoter, and pharmaceutical compositions and methods utilizing same for regulating t-cell mediated immune response |
| 03/07/2002 | CA2418041A1 Pyrrolidine derivatives and their use as chymase inhibitor |
| 03/06/2002 | EP1184388A1 Sulphostin analogues and processes for the preparation of sulphostin and analogues thereof |
| 03/06/2002 | EP1184376A1 Novel heterocyclic carboxamide derivatives |
| 03/06/2002 | EP1184034A2 Oral drug composition containing a verapamil derivative as a drug-absorption promotor |
| 03/06/2002 | EP1183382A2 Method for selecting improved vectors |
| 03/06/2002 | EP1183370A2 Human oxidoreductase proteins |
| 03/06/2002 | EP1183367A1 Cytotoxic t-cell epitopes of the papillomavirus l1-protein and use thereof in diagnostics and therapy |
| 03/06/2002 | EP1183360A2 Modified cytokine for its stabilisation |
| 03/06/2002 | EP1183349A1 Tumor-associated antigen (c42) |
| 03/06/2002 | EP1183344A2 Adam polynucleotides and polypeptides |
| 03/06/2002 | EP1183333A1 Methods of using rnase p reaction mechanisms of action |
| 03/06/2002 | EP1183267A1 Retro-inverso peptides derived from interleukin-6 |
| 03/06/2002 | EP1183258A1 Imidazo-containing heterocyclic compounds, their compositions and uses |
| 03/06/2002 | EP1183254A1 Substituted bicyclic heteroaryl compounds as integrin antagonists |
| 03/06/2002 | EP1183251A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents |
| 03/06/2002 | EP1183241A1 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 03/06/2002 | EP1183240A1 Beta2-adrenoceptor agonists |
| 03/06/2002 | EP1183237A1 Novel antioxidants, preparation methods and uses |
| 03/06/2002 | EP1183233A2 Bradykinin receptor antagonists |
| 03/06/2002 | EP1183231A1 Cytofectin dimers and methods of use thereof |
| 03/06/2002 | EP1183047A2 Pharmaceutical preparation |
| 03/06/2002 | EP1183045A2 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response |
| 03/06/2002 | EP1183044A2 Adjuvant combinations for immunization and vaccines |
| 03/06/2002 | EP1183040A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
| 03/06/2002 | EP1183037A2 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 03/06/2002 | EP1183033A1 Pyrrolotriazine inhibitors of kinases |
| 03/06/2002 | EP1183019A2 Ace-2 inhibiting compounds and methods of use thereof |
| 03/06/2002 | EP0873133B1 Biologically active composition comprising cyclosporine |
| 03/06/2002 | EP0819122B1 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity |
| 03/06/2002 | EP0756595B1 Substituted 1,3-oxathiolanes with antiviral properties |
| 03/06/2002 | EP0710110B1 Antibodies of ring opened rapamycins |
| 03/06/2002 | EP0703784B1 Release and mobilisation of haematopoietic cells |
| 03/06/2002 | CN1339068A Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane |
| 03/06/2002 | CN1338947A Novel mucosal delivery system |
| 03/06/2002 | CN1338942A Self-emulsifying compositions for drugs poorly soluble in water |
| 03/06/2002 | CN1338941A High molecular weight extracts of 1 (convolvulus arvensis) (field bindweed) |
| 03/06/2002 | CN1338940A Bidifobacterium in the treatment of inflammatory disease |
| 03/06/2002 | CN1338936A Drug-combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 |
| 03/06/2002 | CN1338933A Methods and compositions to enhance white blood cell count |
| 03/06/2002 | CN1338923A Method for controlling liposome size |
| 03/06/2002 | CN1338304A Health-care 'Genoderma King' |
| 03/06/2002 | CN1080311C Peptide related to human programmed cell death and DNA cencoding it |
| 03/06/2002 | CN1080264C Oxathiolanes, method for their preparation and pharmaceutical compoistions containing same |
| 03/06/2002 | CN1080262C Novel substituted 4-(1H-benzimidazol-2-YL)[1,4] diazepanes useful for the treatment of allergic diseases |
| 03/06/2002 | CN1080120C Pharmaceutical compositions |
| 03/05/2002 | US6353010 Enzyme inhibitors tumor necrosis factor and phosphodiesterase for antiinflammatory agents |
| 03/05/2002 | US6353007 Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents |
| 03/05/2002 | US6352989 Nitrogenous heterocyclic derivatives and medicine thereof |
| 03/05/2002 | US6352975 Methods of treating hypertension and compositions for use therein |
| 03/05/2002 | US6352832 Anti-CCR2 antibodies and methods of use therefor |
| 03/05/2002 | US6352697 Immunostimulating complex matrices; quil a fractions |
| 03/05/2002 | CA2356553A1 Identification of a capacitative calcium channel in antigen presenting cells and uses thereof |
| 03/05/2002 | CA2266565C Azabicyclic rotomase inhibitors |
| 03/05/2002 | CA2215013C N-substituted indol-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action |
| 02/28/2002 | WO2002016597A2 Lipid metabolism enzymes |
| 02/28/2002 | WO2002016587A2 Microtubule-associated proteins and tubulins |
| 02/28/2002 | WO2002016560A1 Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells |
| 02/28/2002 | WO2002016549A2 METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE |
| 02/28/2002 | WO2002016436A2 ANTIBODIES TO HUMAN IL-1$g(b) |
| 02/28/2002 | WO2002016434A1 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION |
| 02/28/2002 | WO2002016413A2 Cripto tumour polypeptide |
| 02/28/2002 | WO2002016410A2 Peptide selection method |
| 02/28/2002 | WO2002016409A2 Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
| 02/28/2002 | WO2002016394A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds |
| 02/28/2002 | WO2002016393A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016392A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016381A2 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | WO2002016370A1 1h-imidazopyridine derivatives |
| 02/28/2002 | WO2002016368A1 Process for the preparation and purification of thiol-containing maytansinoids |
| 02/28/2002 | WO2002016359A1 Fused pyrazole derivatives being protein kinase inhibitors |
| 02/28/2002 | WO2002016353A1 Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders |
| 02/28/2002 | WO2002016326A1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases |
| 02/28/2002 | WO2002016324A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 02/28/2002 | WO2002016313A2 Integrin receptor inhibitors |
| 02/28/2002 | WO2002016311A1 Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 02/28/2002 | WO2002015977A2 Methods and compositions for treating ige-related disease using nnt-1 inhibitors |
| 02/28/2002 | WO2002015930A1 Adjuvant |
| 02/28/2002 | WO2002015929A1 Methods and compositions for use in the diagnosis and treatment of chronic immune disease |
| 02/28/2002 | WO2002015923A1 Orally administered peptides to ameliorate atherosclerosis |
| 02/28/2002 | WO2002015920A2 Treatment of hyperproliferative diseases |
| 02/28/2002 | WO2002015917A1 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 02/28/2002 | WO2002015915A2 Method for inducing an anti-tumor and anti-cachexia immune response in mammals |